BROWSE

Related Researcher

Author's Photo

Choi, Jang Hyun
Lab of Diabetes and Metabolism (LDM)
Research Interests
  • Diabetes, Metabolic Disorders, PPARg, Gene Regulation, Anti-Diabetic Drug

ITEM VIEW & DOWNLOAD

N-Acetylfarnesylcysteine Is a Novel Class of Peroxisome Proliferator-activated Receptor gamma Ligand with Partial and Full Agonist Activity in Vitro and in Vivo

Cited 13 times inthomson ciCited 8 times inthomson ci
Title
N-Acetylfarnesylcysteine Is a Novel Class of Peroxisome Proliferator-activated Receptor gamma Ligand with Partial and Full Agonist Activity in Vitro and in Vivo
Author
Bhalla, KavitaHwang, Bor JangChoi, Jang HyunDewi, RubyOu, LihuiMclenithan, JohnTwaddel, WilliamPozharski, EdwinStock, JeffryGirnum, Geoffrey D.
Issue Date
2011-12
Publisher
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
Citation
JOURNAL OF BIOLOGICAL CHEMISTRY, v.286, no.48, pp.41626 - 41635
Abstract
The thiazolidedione (TZD) class of drugs is clinically approved for the treatment of type 2 diabetes. The therapeutic actions of TZDs are mediated via activation of peroxisome proliferator-activated receptor gamma (PPAR gamma). Despite their widespread use, concern exists regarding the safety of currently used TZDs. This has prompted the development of selective PPAR gamma modulators (SPPARMs), compounds that promote glucose homeostasis but with reduced side effects due to partial PPAR gamma agonism. However, this also results in partial agonism with respect to PPAR gamma target genes promoting glucose homeostasis. Using a gene expression-based screening approach we identified N-acetylfarnesylcysteine (AFC) as both a full and partial agonist depending on the PPAR gamma target gene (differential SPPARM). AFC activated PPAR gamma as effectively as rosiglitazone with regard to Adrp, Angpt14, and AdipoQ, but was a partial agonist of aP2, a PPAR gamma target gene associated with increased adiposity. Induction of adipogenesis by AFC was also attenuated compared with rosiglitazone. Reporter, ligand binding assays, and dynamic modeling demonstrate that AFC binds and activates PPAR gamma in a unique manner compared with other PPAR gamma ligands. Importantly, treatment of mice with AFC improved glucose tolerance similar to rosiglitazone, but AFC did not promote weight gain to the same extent. Finally, AFC had effects on adipose tissue remodeling similar to those of rosiglitazone and had enhanced antiinflammatory effects. In conclusion, we describe a new approach for the identification of differential SPPARMs and have identified AFC as a novel class of PPAR gamma ligand with both full and partial agonist activity in vitro and in vivo.
URI
https://scholarworks.unist.ac.kr/handle/201301/7221
URL
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=82355184494
DOI
10.1074/jbc.M111.257915
ISSN
0021-9258
Appears in Collections:
BIO_Journal Papers
Files in This Item:
There are no files associated with this item.

find_unist can give you direct access to the published full text of this article. (UNISTARs only)

Show full item record

qrcode

  • mendeley

    citeulike

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

MENU